✦ LIBER ✦

Interleukin-21 + sorafenib promising for renal cancer

Book ID: 120842599
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2008
Weight: 120 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200816620-00045

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Recombinant interleukin-21 plus sorafeni

Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study

✍ Bhatia, Shailender; Curti, Brendan; Ernstoff, Marc S; Gordon, Michael; Heath, El 📂 Article 📅 2014 🏛 Springer (Biomed Central Ltd.) 🌐 English ⚖ 365 KB

Sorafenib a worthy opponent for advanced

Sorafenib a worthy opponent for advanced renal cancer

📂 Article 📅 2007 🏛 Adis International Limited (now part of Wolters Kl ⚖ 120 KB

Sorafenib and Sunitinib: Novel Targeted

Sorafenib and Sunitinib: Novel Targeted Therapies for Renal Cell Cancer

✍ Dr. Cheryl A. Grandinetti; Dr. Barry R. Goldspiel 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 352 KB

Dendritic cell-based immunotherapy promi

Dendritic cell-based immunotherapy promising for renal cancer

📂 Article 📅 1999 🏛 Adis International Limited (now part of Wolters Kl ⚖ 249 KB

Interleukin 21: combination strategies f

Interleukin 21: combination strategies for cancer therapy

✍ Skak, Kresten; Kragh, Michael; Hausman, Diana; Smyth, Mark J.; Sivakumar, Pallav 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 773 KB

Interleukin 21: combination strategies f

Interleukin 21: combination strategies for cancer therapy

✍ Skak, Kresten; Kragh, Michael; Hausman, Diana; Smyth, Mark J.; Sivakumar, Pallav 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 96 KB